Table 1.
Patient Characteristics: Active Disease Cohort
| UPN | Age (years) | Sex | Disease/EBV Latency Type | No. of Relapses | Most Recent Treatment | ALC at Time of Infusion | Total CTL Dose | Toxicity Attributed to CTLs | Response to CTLs | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| LMP2-specific CTL protocol | ||||||||||
| 824 | 8 | M | T-cell CAEBV, latency II | 2 | AlloSCT (busulfan/cyclophosphamide/alemtuzumab) | 728 | 4 × 107/m2 | None | PR | Relapse at 4 years |
| 652 | 39 | M | DLBCL, latency II | 5 | Brentuximab | 649 | 8 × 107/m2 | None | CR | Relapse at 10 months |
| 909 | 30 | F | HL/CVID, latency III | 2 | ABVD, rituximab | 4,998 | 8 × 107/m2 | None | CR | Durable CR (9+ years) |
| 1316 | 54 | M | NK/T-cell NHL, latency II | 0 | RT, CHOP | 802 | 1.2 × 108/m2 | None | CR | Durable CR (5+ years) |
| 1187 | 17 | M | HL, latency II | 3 | AutoSCT (BEAM) | 334 | 1.2 × 108/m2 | None | NR | NR |
| 1006 | 19 | M | HL, latency II | 6 | ESHAP | 390 | 1.2 × 108/m2 | None | NR | NR |
| 1160 | 15 | F | HL/CVID, latency III | 0 | VP16, doxorubicin, rituximab | 1,483 | 3 × 108/m2 | None | CR | Durable CR (7+ years) |
| 1054 | 64 | F | NK/T-cell NHL, latency II | 3 | R-CHOP | 479 | 3.2 × 108/m2 | None | CR | Relapse at 9 months |
| LMP1/2-specific CTL protocol | ||||||||||
| 1372 | 69 | M | NK/T-cell NHL, latency II | 1 | CHOP, RT | 671 | 4 × 107/m2 | None | CR | Durable CR (5+ years) |
| 1371 | 21 | M | HL, post-SOT, latency III | 1 | Ifosfamide, vinorelbine, Ara-C, VP16, cisplatin, RT | 476 | 4 × 107/m2 | None | CR | Durable CR (5+ years) |
| 2051 | 30 | F | T-cell CAEBV, latency II | 0 | CHOP, VP16, dexamethasone, acyclovir | 1,308 | 4 × 107/m2 | None | NR | NR |
| 2336 | 52 | M | DLBCL/PTLD, latency III | 0 | No treatment | 444 | 4 × 107/m2 | None | CR | Durable CR (2+ years) |
| 2266 | 27 | F | HL, latency II | 3 | SGN-35, bendamustine | 446 | 4 × 107/m2 | None | NR | NR |
| 2457 | 16 | M | HL, latency II | 0 | COG protocol (AHOD0031) | 1,332 | 4 × 107/m2 | None | NR | NR |
| 1811 | 60 | M | NK/T-cell NHL, latency II | 0 | RT, hyperCVAD, high-dose MTX | 411 | 1 × 108/m2 | Inflammatory response? | NR | NR |
| 1409 | 18 | M | NK/T-cell NHL, latency II | 0 | RT, CHOP | 413 | 1.2 × 108/m2 | None | NR | NR |
| 1545 | 79 | M | LYG, latency III | 0 | No treatment | 659 | 1.2 × 108/m2 | None | CR | Durable CR (4+ years) |
| 1351 | 46 | F | HL, latency II | 3 | AutoSCT (BEAM) | 1,889 | 2 × 108/m2 | None | PR | Received T cells on second protocol → durable CR (5+ years) |
| 1356 | 28 | F | DLBCL, latency II | 1 | No treatment | 1,730 | 3 × 108/m2 | None | NR | NR |
| 1990 | 65 | M | CLL/DLBCL, latency III | 0 | FCR, alemtuzumab | 732 | 3 × 108/m2 | Inflammatory response? | CR | Durable CR (1+ year); died as result of infection |
| 1656 | 55 | M | NK/T-cell NHL, latency II | 0 | RT | 808 | 5 × 108/m2 | None | PR → CR | Durable CR (4+ years) |
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; ALC, absolute lymphocyte count; alloSCT, allogeneic stem-cell transplantation; Ara-C, cytarabine; autoSCT, autologous SCT; BEAM, carmustine, etoposide, cytarabine, melphalan; CAEBV, chronic active EBV infection; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CLL, chronic lymphocytic leukemia; COG, Children's Oncology Group; CR, complete response; CTL, cytotoxic T lymphocyte; CVID, common variable immunodeficiency disease; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; FCR, fludarabine, cyclophosphamide, rituximab; HL, Hodgkin lymphoma; hyperCVAD, cyclophosphamide, doxorubicin, vincristine, dexamethasone, cytarabine, methotrexate; LMP, latent membrane protein; LYG, lymphoid granulomatosis; MTX, methotrexate; NHL, non-Hodgkin lymphoma; NK, natural killer; NR, no response; PR, partial response; PTLD, post-transplantation lymphoproliferative disease; R-CHOP, rituximab plus CHOP; RT, radiation therapy; SGN-35, brentuximab vedotin; SOT, solid organ transplantation; UPN, unique patient number; VP16, etoposide.